Denzapine is indicated in treatment resistant schizophrenic patients and in schizophrenia patients who have severe, untreatable neurological adverse reactions to other antipsychotic agents, including atypical antipsychotics.
The company said that Denzapine is available in the market in 25mg, 50mg, 100mg, and 200mg tablet strengths and as 50mg/m in an oral suspension form.
Clozapine is used to treat severe schizophrenia symptoms in people who have not responded to other medications. It is also used to help reduce the risk of suicidal behavior in people with schizophrenia or similar disorders.
Clozapine works against positive (eg delusions, hallucinations) and negative (eg emotional and social withdrawal) symptoms of schizophrenia. It has no dyscognitive effect often seen with other psychoactive drugs and is even able to increase the capabilities of the patient to react to this environment and thereby fosters social rehabilitation.
Stuart Rose, managing director of UK & Ireland at Merz Pharma, said: “The launch of Denzapine in Ireland brings an important choice in the field of treatment-resistant schizophrenia to Ireland for the fist time and marks a milestone in Merz’s ongoing international expansion,” reports the website.